Oncology

Back to articles

Ibrutinib beats ofatumumab in chronic lymphoid leukemia

KEY POINT

The oral agent ibrutinib (Imbruvica—Pharmacyclics, Janssen Biotech) was associated with improved progression-free survival, overall survival, and response rates compared with ofatumumab (Arzerra—GlaxoSmithKline) in patients with previously treated chronic lymphoid leukemia (CLL) or small lymphocytic leukemia (SLL), according to a recent study.